Patent · US Active

Treating cancer using electromagnetic fields in combination with other treatment regimens

US8406870B2 · kind B2 · utility

102Cited by
63References
14Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 24, 2011
Grant dateMar 26, 2013
Priority date—
Expiry dateAug 24, 2031

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61N1/326
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.